Gsk plc
Congress has disclosed 43 buys and 22 sells of GSK (Gsk plc) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying GSK and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Marjorie Taylor Greene | 2024-11-25 | $31.90 | $49.51 | +55.2% | in profit |
| Alan Armstrong | 2026-03-30 | $53.26 | $49.51 | -7.0% | underwater |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Legislation Related Legislation
Recent bills in this stock's sector (). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
65 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | BUY | Self | 2026-03-30 | 113 days | -5.5% | $15K–$50K | 99.6 | ↗ eFD |
| Lisa McClain | House | SELL ◆ insider divergence | Spouse · Charles Schwab 401K > Schwab 893 | 2025-10-31 | 1 days | 0.0% | $1K–$15K 0.1% of NW |
60.5 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider convergence | Spouse · Charles Schwab 401K > Schwab 893 | 2025-10-30 | 2 days | -0.2% | $1K–$15K 0.1% of NW |
65.2 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider divergence | Spouse · Charles Schwab Brokerage Account 924 | 2025-10-30 | 2 days | -0.2% | $1K–$15K 0.1% of NW |
65.2 | ↗ filing |
| Valerie Hoyle | House | SELL | Spouse · Fidelity Rollover IRA | 2025-09-23 | 0 days | 0.0% | $1K–$15K 0.8% of NW |
30.3 | ↗ filing |
| Lisa McClain | House | BUY | Spouse · Charles Schwab Brokerage Account 924 | 2025-08-04 | 9 days | +3.8% | $1K–$15K 0.1% of NW |
67.1 | ↗ filing |
| Robert Aderholt | House | SELL | Self | 2025-07-28 | 14 days | +0.7% | $1K–$15K 0.1% of NW |
93.5 | ↗ filing |
| Lisa McClain | House | SELL | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-24 | 50 days | +1.2% | $1K–$15K 0.1% of NW |
84.7 | ↗ filing |
| Lisa McClain | House | BUY | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-17 | 57 days | -1.5% | $1K–$15K 0.1% of NW |
97.3 | ↗ filing |
| Bruce Westerman | House | SELL | Self · Fisher IRA | 2025-04-21 | 7 days | +4.4% | $1K–$15K 0.7% of NW |
30.1 | ↗ filing |
| Bruce Westerman | House | BUY | Self · Fisher IRA | 2025-03-03 | 14 days | +6.1% | $1K–$15K 0.7% of NW |
65.4 | ↗ filing |
| Marjorie Taylor Greene | House | BUY ◆ insider convergence | Self | 2024-11-25 | 1 days | -0.4% | $1K–$15K | 52.4 | ↗ filing |
| Valerie Hoyle | House | BUY ◆ insider convergence | Spouse · Fidelity Rollover IRA | 2024-11-18 | 297 days | +27.3% | $1K–$15K 0.8% of NW |
69.5 | ↗ filing |
| Marjorie Taylor Greene | House | BUY ◆ insider convergence | Self | 2024-09-03 | 1 days | +1.9% | $1K–$15K | 75.9 | ↗ filing |
| Daniel Goldman | House | SELL | Self · Daniel Goldman Grandchildren 1986 Trust > TLH ADR | 2023-07-10 | 25 days | — | $15K–$50K <0.1% of NW |
90.9 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-08-16 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-08-09 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | SELL | Joint | 2022-07-12 | 0 days | — | $100K–$250K 3.9% of NW 🔥 |
95.4 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-07-06 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-04-08 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-02-22 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| John Rutherford | House | SELL | Self | 2022-02-17 | 0 days | — | $1K–$15K 0.8% of NW |
40.5 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2022-01-14 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2021-10-08 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2021-07-09 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Katherine Clark | House | SELL | Spouse | 2021-06-04 | 70 days | — | $1K–$15K 0.1% of NW |
8.6 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2021-04-09 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2021-01-15 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Katherine Clark | House | BUY | Spouse | 2020-11-05 | 53 days | — | $1K–$15K 0.1% of NW |
19.6 | ↗ filing |
| Katherine Clark | House | SELL | Spouse | 2020-10-22 | 36 days | — | $1K–$15K 0.1% of NW |
15.7 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2020-10-09 | 0 days | — | $1K–$15K 0.2% of NW |
82.5 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2020-07-10 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2020-04-13 | 0 days | — | $15K–$50K 0.7% of NW |
85.1 | ↗ filing |
| Katherine Clark | House | BUY | Spouse | 2020-03-02 | 43 days | — | $1K–$15K 0.1% of NW |
22.3 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2020-01-10 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2019-10-11 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2019-07-12 | 0 days | — | $1K–$15K 0.2% of NW |
66.2 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2019-04-12 | 0 days | — | $1K–$15K 0.2% of NW |
66.5 | ↗ filing |
| Nicholas Taylor | House | SELL | Spouse | 2019-03-25 | 0 days | — | $15K–$50K | 90.9 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2019-01-10 | 0 days | — | $1K–$15K 0.2% of NW |
67.0 | ↗ filing |
| Greg Gianforte | House | SELL | Joint | 2018-12-21 | 5 days | — | $15K–$50K | 48.0 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2018-12-11 | 0 days | — | $15K–$50K 0.7% of NW |
88.4 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2018-10-09 | 0 days | — | $1K–$15K 0.2% of NW |
69.3 | ↗ filing |
| Zoe Lofgren | House | SELL | Spouse | 2018-08-30 | 14 days | — | $1K–$15K 0.1% of NW |
40.5 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2018-04-12 | 0 days | — | $1K–$15K 0.2% of NW |
86.9 | ↗ filing |
| Greg Gianforte | House | BUY OTHER | Joint | 2018-03-26 | 7 days | — | $1K–$15K | 52.4 | ↗ filing |
| Katherine Clark | House | SELL | Spouse | 2018-01-03 | 36 days | — | $1K–$15K 0.1% of NW |
52.4 | ↗ filing |
| Greg Gianforte | House | SELL | Joint | 2017-12-14 | 4 days | — | $50K–$100K | 96.1 | ↗ filing |
| Kenneth Buck | House | SELL | Self | 2017-11-07 | 6 days | — | $1K–$15K 3.9% of NW 🔥 |
40.5 | ↗ filing |
| Kenneth Buck | House | BUY | Self | 2017-10-27 | 5 days | — | $1K–$15K 3.9% of NW 🔥 |
93.1 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2017-10-25 | 0 days | — | $1K–$15K 0.2% of NW |
93.9 | ↗ filing |
| Pete Sessions | House | BUY | Spouse | 2017-10-25 | 0 days | — | $1K–$15K 0.2% of NW |
95.8 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2017-10-24 | 0 days | — | $1K–$15K 0.2% of NW |
95.8 | ↗ filing |
| Pete Sessions | House | SELL | Spouse | 2017-08-31 | 0 days | — | $1K–$15K 0.2% of NW |
94.6 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2017-08-04 | 0 days | — | $15K–$50K 0.7% of NW |
98.1 | ↗ filing |
| John Rutherford | House | BUY | Self | 2017-07-11 | 20 days | — | $1K–$15K 0.8% of NW |
93.1 | ↗ filing |
| Zoe Lofgren | House | BUY | Spouse | 2017-06-15 | 27 days | — | $1K–$15K 0.1% of NW |
86.9 | ↗ filing |
| Charlie Joseph Crist | House | SELL | Self | 2017-02-22 | 13 days | — | $50K–$100K | 96.3 | ↗ filing |
| Pete Sessions | House | BUY | Spouse | 2016-12-01 | 0 days | — | $1K–$15K 0.2% of NW |
98.8 | ↗ filing |
| Katherine Clark | House | BUY | Spouse | 2016-10-11 | 197 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Scott Rigell | House | BUY | Spouse | 2016-03-08 | 23 days | — | $15K–$50K | 94.9 | ↗ filing |
| Virginia Foxx | House | BUY | Joint | 2016-02-11 | 0 days | — | $15K–$50K 0.7% of NW |
99.8 | ↗ filing |
| Thomas MacArthur | House | SELL | Self | 2015-05-27 | 5 days | — | $1K–$15K | 86.9 | ↗ filing |
| Michael Conaway | House | SELL | Spouse | 2015-04-27 | 3 days | — | $1K–$15K | 86.9 | ↗ filing |
| Thomas Rooney | House | SELL | Self | 2014-07-29 | 31 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in GSK — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in GSK, 4 coincided with corporate insiders moving the same way within 60 days, and 2 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2025-12-11 | GSK plc | Other | BUY | $27.9M | ↗ EDGAR |
| 2024-09-27 | GSK plc | Other | BUY | $22.3M | ↗ EDGAR |
| 2023-12-07 | GSK plc | Other | BUY | $16.5M | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| Congress | 2026-03-30 | Alan Armstrong | BUY | $15K–$50K |
| ◆ insider | 2025-12-11 | GSK plc Other | BUY | $27.9M |
| Congress | 2025-10-31 | Lisa McClain | SELL | $1K–$15K |
| Congress | 2025-10-30 | Lisa McClain | BUY | $1K–$15K |
| Congress | 2025-10-30 | Lisa McClain | SELL | $1K–$15K |
| Congress | 2025-09-23 | Valerie Hoyle | SELL | $1K–$15K |
| Congress | 2025-08-04 | Lisa McClain | BUY | $1K–$15K |
| Congress | 2025-07-28 | Robert Aderholt | SELL | $1K–$15K |
| Congress | 2025-06-24 | Lisa McClain | SELL | $1K–$15K |
| Congress | 2025-06-17 | Lisa McClain | BUY | $1K–$15K |
| Congress | 2025-04-21 | Bruce Westerman | SELL | $1K–$15K |
| Congress | 2025-03-03 | Bruce Westerman | BUY | $1K–$15K |
| Congress | 2024-11-25 | Marjorie Taylor Greene | BUY | $1K–$15K |
| Congress | 2024-11-18 | Valerie Hoyle | BUY | $1K–$15K |
| ◆ insider | 2024-09-27 | GSK plc Other | BUY | $22.3M |
| Congress | 2024-09-03 | Marjorie Taylor Greene | BUY | $1K–$15K |
| ◆ insider | 2023-12-07 | GSK plc Other | BUY | $16.5M |
| Congress | 2023-07-10 | Daniel Goldman | SELL | $15K–$50K |
| Congress | 2022-08-16 | Virginia Foxx | BUY | $1K–$15K |
| Congress | 2022-08-09 | Virginia Foxx | BUY | $1K–$15K |
| Congress | 2022-07-12 | Virginia Foxx | SELL | $100K–$250K |
| Congress | 2022-07-06 | Virginia Foxx | BUY | $1K–$15K |
| Congress | 2022-04-08 | Virginia Foxx | BUY | $1K–$15K |
| Congress | 2022-02-22 | Virginia Foxx | BUY | $1K–$15K |
FAQ Common questions
How much has Congress traded GSK?
43 disclosed buys and 22 sells of GSK (Gsk plc) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade GSK?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.